Antimicrobial agent for animals

Abstract: An antimicrobial agent for animals is disclosed. The agent comprises as an effective component a racemate or a 3S-type compoundof of a pyrido[1,2,3-de] [1,4]benzoxazine derivative represented by the formula (I): wherein R is a C₁₋₆ alkyl group, provided that R cannot be a methyl group when the pyrido[1,2,3-de] [1,4]benzoxazine derivative is a racemate, or a salt or a hydrate thereof. The compound gives a low toxic, safe antimicrobial agent for animals, has a broader antimicrobial spectrum, and is effective against various infectious diseases of animals.

Description: BACKGROUND OF THE INVENTION Field of the Invention : This invention relates to a use of a 3S-type compound selected from pyrido[1,2,3-de][1,4]benzoxazine derivatives represented by the formula (I): wherein R is a C₁₋₆ alkyl group, or a salt or a hydrate thereof, for the prevention, cure, or treatment of various infectious diseases of animals. Description of the Background : The increased number of livestock and poultry confined to a unit area by the current stockbreeding practices gives rise to proliferation of various infectious disease among farm animals and domestic birds. Damage caused by such infectious diseases has been increasing yearly, posing an economic problem to the industry. Conventionally, antibiotics such as tylosin, oxytetracycline, etc., and synthetic antimicrobial agents such as oxolinic acid, piromidic acid, etc. have been added to feed or water, orally administered, or injected to animals for the prevention and cure of their infectious diseases. These conventional antimicrobial agents, however, have drawbacks such as insufficient antimicrobial activity, a narrow antimicrobial spectrum, development of microbial resistance to the agents, low disease-curing effect, inadequate safety, side effects, high production costs, and the like. Among pyrido[1,2,3-de][1,4]benzoxazine derivatives of the above formula (I) a compound which is a racemate and has no substituted group at the 3-position in formula (I) has been reported in Japanese Patent Laid-open No. 184014/1985. Japanese Patent Laid-open No. 116217/1984 discloses antimycoplasmal activity of ofloxacin. These compound, however, possess only a narrow antimicrobial spectrum, and their antimicrobial activity is not necessarily sufficient. EP-A-0 047 005 describes a use of a racemate of a compound having the above general formula (I). From EP-A-0 206 283, it is known that 3S-type compounds of formula (I) posess a higher anti-microbial actvity than the corresponding racemate or 3R-type compound. It has been found that among the compounds of general formula I (wherein R is a C₁₋₆ alkyl group), the compound 3S-9-fluoro-2,3-dihydro-3-methyl-10-(4-ethyl-1-piperazinyl)-7-oxo-7H-pyrido [1,2,3-de][1,4]benzoxazine-6-carboxylic acid or a salt or a hydrate thereof exhibited a superior preventive or curing effect against a wide variety of infectious diseases of animals with no or little toxicity. Such a finding has led to the completion of this invention. SUMMARY OF THE INVENTION Accordingly, the present invention provides a use of 3S-9-fluoro-2,3-dihydro-3-methyl-10-(4-ethyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid or a salt or a hydrate thereof, in the manufacture of a medicament for treating or preventing infectious diseases of animals. DETAILED DESCRIPTION OF THE INVENTION AND PREFERRED EMBODIMENTS The Compound defined in claim 1 can be used as acid addition salts owing to the basic nature of the piperazinyl group of the 10-position. Examples of acid addition salts include inorganic salts such as hydrochloride, hydrobromide, hydroiodide, sulfate, etc. and organic salts such as acetate, methanesulfonate, citrate, benzenesulfonate, lactate, etc. The carboxy group at the 6-position may take a salt form including alkali metal salts such as sodium salt, potassium salt, etc., alkaline earth metal salts such as magnesium salt, calcium salt, etc., ammonium salts, and organic salts such as triethylamine salt, etc. Furthermore, salts of said Compound can be used in hydrate forms. For the preparation of racemates of Compound (I) the methods described in Japanese Patent Laid-open Nos. 46986/1982 and 72589/1983, for example, can be used. The method described in Japanese Patent Laid-open No. 252790/1987 can be given as an example of the method for preparing 3S-type compounds. The Compound defined in claim 1, their salts or hydrates [hereinafter collectively referred to as Active Compounds (I)] can be dosed to animals by oral administration, as are or mixed with feed. Alternatively, they can be dissolved in water and the solution is orally administered as is, mixed with feed, or further diluted with water. Injection is another method for administrating the Active Compounds (I). The dose depend upon the purpose of the administration, e.g., prevention, cure, etc., kinds and body weight of animals to be treated, types of microorganisms causing the infection, the degree of infection, and the like. In general, 1-200 mg per day, preferably 5-100 mg per day, is dosed once or several times a day. These ranges are, however, an approximate standard, and it is possible to dose Active Compound (I) in an amount outside the above range, depending on the age, body weight, and degree of disease of the animal. There are no specific limitations as to the period during which Active Compound (I) is administered to animals. Usually, the administration for a period of 1-10 days gives a sufficient result. Intermittent administration is also possible. Active Compound (I) can be dosed to animals in various forms of preparations that can be prepared according to conventional methods such as powders, subtilized granules, solubilizable powders, syrups, solutions, injections, and the like. Hereinafter are presented typical formulations comprising Active Compound (I). Formulation Example 1 Preparation for mixing with feed Components Amount (parts by weight) Active Compound (I) 1-10 Corn starch 98.5-89.5 Light anhydrous silicic acid 0.5 Total 100 Formulation Example 2 Preparation for mixing with feed or water Components Amount (parts by weight) Active Compound (I) (Water soluble) 1-10 Lactic acid 90-99 Total 100 Formulation Example 3 Liquid preparation Components Amount (parts by weight) Active Compound (I) 1-10 Acetic acid or sodium hydroxide 5-20 Ethyl parabenzoate 0.1 Purified water 69.6-93.9 Total 100 Antimicrobial agents comprising the active compound used in accordance with the present invention exhibit a wide spectrum of activity against various bacteria causing infectious diseases of animals. They exhibit strong activities against bacteria belonging to genera, for example, of Escherichia , Salmonella , Pasteurella , Haemophilus , Bordetella , Staphylococcus , Mycoplasma , etc. They are therefore useful for the prevention, cure, and treatment of infectious diseases of cattle, pigs, birds, dogs, cats, and the like. Named as specific infectious diseases against which the antimicrobial agent of this invention is effective are; for diseases of cattle, E. coli infection, Salmonella infection, Mycoplasma infection, hemorrhagic septicemia, bovine contiguous pleuropneumonia, mastitis, etc.; for diseases of pigs, E. coli infection, Salmonella infection, Pasteurella infection, Mycoplasma infection, atrophic rhinitis, exudative epidermitis, etc.; for diseases of birds, E. coli infection, chicken pullorum, paratyphoid, bird cholera, infectious coryza, staphylococcus infection, Mycoplasma infection, etc.; for diseases of dogs, E. coli septicemia, Salmonella infection, hemorrhagic septicemia, uterus empyema, cystitis, etc.; and for diseases of cats, pleurisy, cystitis, Haemophilus infection, diarrhea, Mycoplasma infection, etc. EXAMPLES In the following examples Active Compounds listed in Table 1 below were prepared or used. Example 1 Measurement of in vitro antimicrobial activity of Active Compounds (I) against pathogenic bacteria derived from animals (Part 1): Test microorganisms listed in Table 2 were cultured overnight in heart infusion nutrient broth (produced by Eiken Chemical Co., Ltd.). Culture broth containing about 10⁸/ml cells was diluted to a volume of 100 times. An aliquot (about 0.05 ml) of the diluted broth was inoculated onto a Mueller Hinton agar plate (produced by Eiken Chemical Co., Ltd.) to which Compound No. 1 was added in a prescribed concentration. After incubation at 37°C for 18-24 hours, the minimum inhibitory concentration (MIC), i.e., the minimum concentration of Compound No. 1 inhibiting the growth of the inoculated cells, was determined. The results are shown in Table 2. Table 2 shows that Compound No. 1 exhibited higher antimicrobial activities than its known racemic isomer (Ofloxacin). Example 2 Measurement of in vitro antimicrobial activity of Active Compounds (I) against pathogenic bacteria derived from animals (Part 2): MIC of Compounds (1)-(8) against various pathogenic bacteria derived from animals was determined in the same manner as in Example 1. The results are shown in Table 3. As evident from Table 3, Compound Nos. 1-8 exhibited higher in vitro antimicrobial activities than oxolinic acid which is widely used as an antimicrobial agent for animals.

Claims: Claims for the following Contracting States : DE, FR, GB, IT, NL Use of 3S-9-fluoro-2,3-dihydro-3-methyl-10-(4-ethyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid or a salt or a hydrate thereof, in the manufacture of a medicament for treating or preventing infectious diseases of animals. Use of Claim 1, wherein said disease is selected from the group consisting of bovine E. coli infection, bovine Salmonella infection, bovine Mycoplasma infection, bovine hemorrhagic septicemia, bovine contiguous pleuropneumonia, bovine mastitis, porcine E. coli infection, porcine Salmonella infection, porcine Pasteurella infection, porcine Mycoplasma infection, porcine atrophic rhinitis, porcine exudative epidermitis, avian E. coli infection, chicken pullorum, avian paratyphoid, avian cholera, avian infectious coryza, avian staphylococcus infection, avian Mycoplasma infection, canine E. coli septicemia, canine Salmonella infection, canine hemorrhagic septicemia, canine uterus empyema, canine cystitis, feline pleurisy, feline cystitis, feline Haemophilus infection, feline diarrhea, and feline Mycoplasma infection. Claims for the following Contracting States : ES, GR Use of 3S-9-fluoro-2,3-dihydro-3-methyl-10-(4-ethyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid or a salt or a hydrate thereof, in the manufacture of a medicament for treating or preventing infectious diseases of animals. Said medicament being applicable only to animals but not to human. Use of Claim 1, wherein said disease is selected from the group consisting of bovine E. coli infection, bovine Salmonella infection, bovine Mycoplasma infection, bovine hemorrhagic septicemia, bovine contiguous plueropneumonia, bovine mastitis, porcine E. coli infection, porcine Salmonella infection, porcine Pasteurella infection, porcine Mycoplasma infection, porcine atrophic rhinitis, porcine exudative epidermitis, avian E. coli infection, chicken pullorum, avian paratyphoid, avian cholera, avian infectious coryza, avian staphylococcus infection, avian Mycoplasma infection, canine E. coli septicemia, canine Salmonella infection, canine hemorrhagic septicemia, canine uterus empyema, canine cystitis, feline pleurisy, feline cystitis, feline Haemophilus infection, feline diarrhea, and feline Mycoplasma infection.

Inventors: KATO MASAHIRO DAIICHI PHARMACE, MIURA TADAYOSHI DAIICHI PHARMA, TAKAHATA TOSHIHIRO DAIICHI PHA, TAKEI MASAKAZU DAIICHI PHARMAC, YOSHIOKA TOSHIYUKI DAIICHI PHA, KATO, MASAHIRO DAIICHI PHARMACEUTICAL, MIURA, TADAYOSHI DAIICHI PHARMACEUTICAL, TAKAHATA, TOSHIHIRO DAIICHI PHARMACEUTICAL, TAKEI, MASAKAZU DAIICHI PHARMACEUTICAL, YOSHIOKA, TOSHIYUKI DAIICHI PHARMACEUTICAL
Applicants: DAIICHI SEIYAKU CO, DAIICHI PHARMACEUTICAL CO., LTD.
Application year: 1989
Main classification: A61K31
IPC codes: A61K31